NF-κB Pathway and Its Inhibitors: A Promising Frontier in the Management of Alzheimer’s Disease

The nuclear factor kappa B (NF-κB) pathway has emerged as a pivotal player in the pathogenesis of various diseases, including neurodegenerative illnesses like Alzheimer’s disease (AD). The involvement of the NF-κB pathway in immune system responses, inflammation, oxidative stress, and neuronal survival highlights its significance in AD progression. We discuss the advantages of NF-κB pathway inhibition, including the potential to mitigate neuroinflammation, modulate amyloid beta (Aβ) production, and promote neuronal survival. However, we also acknowledge the limitations and challenges associated with this approach. Balancing the fine line between dampening inflammation and preserving physiological immune responses is critical to avoid unintended consequences. This review combines current knowledge on the NF-κB pathway’s intricate involvement in AD pathogenesis, emphasizing its potential as a therapeutic target. By evaluating both advantages and limitations, we provide a holistic view of the feasibility and challenges of NF-κB pathway modulation in AD treatment. As the quest for effective AD therapies continues, an in-depth understanding of the NF-κB pathway’s multifaceted roles will guide the development of targeted interventions with the potential to improve AD management.

[1]  Z. Ke,et al.  Micheliolide attenuates neuroinflammation to improve cognitive impairment of Alzheimer's disease by inhibiting NF-κB and PI3K/Akt signaling pathways , 2023, Heliyon.

[2]  M. Kamel,et al.  Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer’s Disease in Rat Model , 2023, International journal of nanomedicine.

[3]  L. Burns,et al.  Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes , 2023, Frontiers in Aging.

[4]  Ke Shi,et al.  [Mechanisms of moxibustion preconditioning underlying improving learning-memory ability by regulating polarization of microglia via TLR4/NF-κB signaling pathway in AD rats]. , 2023, Zhen ci yan jiu = Acupuncture research.

[5]  M. Hosney,et al.  Therapeutic potential of stem cells and acitretin on inflammatory signaling pathway-associated genes regulated by miRNAs 146a and 155 in AD-like rats , 2023, Scientific reports.

[6]  E. Langley,et al.  Prolactin-induced neuroprotection against excitotoxicity is mediated via PI3K/AKT and GSK3β/NF-κB in primary cultures of hippocampal neurons , 2023, Peptides.

[7]  Nguyen Minh Trang,et al.  Citropten Ameliorates Osteoclastogenesis Related to MAPK and PLCγ/Ca2+ Signaling Pathways through the Regulation of Amyloid Beta. , 2023, Journal of agricultural and food chemistry.

[8]  A. Mardinoğlu,et al.  Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients , 2023, Journal of Translational Medicine.

[9]  Xiuhong Zhang,et al.  Diversified cassane family diterpenoids from the leaves of Caesalpinia minax exerting anti-neuroinflammatory activity through suppressing MAPK and NF-κB pathways in BV-2 microglia. , 2023, Journal of ethnopharmacology.

[10]  Qing Shen,et al.  Molecular mechanisms and therapeutic potential of icariin in the treatment of Alzheimer's disease. , 2023, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[11]  K. Skalicka‐Woźniak,et al.  NLRP3 inflammasome inhibition and M1-to-M2 microglial polarization shifting via scoparone-inhibited TLR4 axis in ovariectomy/D-galactose Alzheimer's disease rat model. , 2023, International immunopharmacology.

[12]  Yimin Yan,et al.  Baicalein ameliorates Alzheimer's disease via orchestration of CX3CR1/NF-κB pathway in a triple transgenic mouse model. , 2023, International immunopharmacology.

[13]  Qingyuan Li,et al.  Andrographolide exerts a neuroprotective effect by regulating the LRP1-mediated PPARγ/NF-κB pathway. , 2023, European Journal of Pharmacology.

[14]  J Zhang,et al.  Kai-Xin-San improves cognitive impairment via Wnt/β-catenin and IRE1/XBP1s signalings in APP/PS1 mice. , 2023, Rejuvenation research.

[15]  R. Bhatti,et al.  Neuroprotective potential of biochanin-A and review of the molecular mechanisms involved , 2023, Molecular Biology Reports.

[16]  B. Fiebich,et al.  Licochalcone A Inhibits Prostaglandin E2 by Targeting the MAPK Pathway in LPS Activated Primary Microglia , 2023, Molecules.

[17]  C. Humpel,et al.  Melatonin Activates Anti-Inflammatory Features in Microglia in a Multicellular Context: Evidence from Organotypic Brain Slices and HMC3 Cells , 2023, Biomolecules.

[18]  HuiMin Li,et al.  [Mechanism of Berberis atrocarpa anthocyanin against Alzheimer's disease based on network pharmacology and experimental verification]. , 2023, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[19]  Yongyan Xie,et al.  [Effect of Erjing Pills on alleviating neuroinflammation of AD rats based on TLR4/NF-κB/NLRP3 pathway and its mechanism]. , 2023, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[20]  T. Efferth,et al.  Essential oil of Acorus tatarinowii Schott inhibits neuroinflammation by suppressing NLRP3 inflammasome activation in 3 × Tg-AD transgenic mice. , 2023, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[21]  Mahsa Yousefpour Marzbali,et al.  How do nuclear factor kappa B (NF-κB)1 and NF-κB2 defects lead to the incidence of clinical and immunological manifestations of inborn errors of immunity? , 2023, Expert review of clinical immunology.

[22]  Shamsher Singh,et al.  Neuroprotective potential of Honokiol in ICV-STZ induced neuroinflammation, Aβ (1−42) and NF-kB expression in experimental model of rats , 2023, Neuroscience Letters.

[23]  K. Soliman,et al.  The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer’s Disease , 2023, Brain sciences.

[24]  J. Mudgal,et al.  Avanafil mediated dual inhibition of IKKβ and TNFR1 in an experimental paradigm of Alzheimer’s disease: in silico and in vivo approach , 2022, Journal of biomolecular structure & dynamics.

[25]  Rongping Zhang,et al.  Baicalin Mitigates the Neuroinflammation through the TLR4/MyD88/NF-κB and MAPK Pathways in LPS-Stimulated BV-2 Microglia , 2022, BioMed research international.

[26]  T. Kanda,et al.  Pioglitazone Attenuates the Effects of Peripheral Inflammation in a Human In Vitro Blood–Brain Barrier Model , 2022, International journal of molecular sciences.

[27]  Kuo-Hsuan Chang,et al.  Isorhamnetin Attenuated the Release of Interleukin-6 from β-Amyloid-Activated Microglia and Mitigated Interleukin-6-Mediated Neurotoxicity , 2022, Oxidative medicine and cellular longevity.

[28]  V. Wang,et al.  Atypical IκB Bcl3 enhances the generation of the NF-κB p52 homodimer , 2022, Frontiers in Cell and Developmental Biology.

[29]  M. Aldubayan,et al.  Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature , 2022, Drug design, development and therapy.

[30]  Wei-Chieh Huang,et al.  Activation of Nrf2 by Esculetin Mitigates Inflammatory Responses through Suppression of NF-κB Signaling Cascade in RAW 264.7 Cells , 2022, Molecules.

[31]  W. Lukiw,et al.  Downregulation of Neurofilament Light Chain Expression in Human Neuronal-Glial Cell Co-Cultures by a Microbiome-Derived Lipopolysaccharide-Induced miRNA-30b-5p , 2022, Frontiers in Neurology.

[32]  Janna H. Neltner,et al.  Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts , 2022, Acta Neuropathologica.

[33]  A. Secondo,et al.  Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes , 2022, Frontiers in Pharmacology.

[34]  Gavin Y. Wang,et al.  BAY 11-7082 inhibits the secretion of interleukin-6 by senescent human microglia. , 2022, Biochemical and biophysical research communications.

[35]  Liu Yang,et al.  Hyodeoxycholic acid inhibits lipopolysaccharide-induced microglia inflammatory responses through regulating TGR5/AKT/NF-κB signaling pathway , 2022, Journal of psychopharmacology.

[36]  M. J. Byrnes,et al.  Alzheimer’s Disease: Epidemiology and Clinical Progression , 2022, Neurology and Therapy.

[37]  S. Nahashon,et al.  Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age , 2022, Biomolecules.

[38]  I. Clark Basic Scientific Evidence Consistent with Etanercept Efficacy Against Alzheimer's Disease , 2021, Neuroscience.

[39]  F. Oswald,et al.  IKK2/NF-κB Activation in Astrocytes Reduces amyloid β Deposition: A Process Associated with Specific Microglia Polarization , 2021, Cells.

[40]  A. Alexiou,et al.  Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease , 2021, Current neuropharmacology.

[41]  Yuquan Wei,et al.  Role of lysosomes in physiological activities, diseases, and therapy , 2021, Journal of Hematology & Oncology.

[42]  L. Grinberg,et al.  Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy , 2021, Nature Communications.

[43]  Yaohua Hu,et al.  Reduction BACE1 expression via suppressing NF-κB mediated signaling by Tamibarotene in a mouse model of Alzheimer’s disease , 2021, IBRO neuroscience reports.

[44]  N. Song,et al.  Platycodin D Inhibits β-Amyloid-Induced Inflammation and Oxidative Stress in BV-2 Cells Via Suppressing TLR4/NF-κB Signaling Pathway and Activating Nrf2/HO-1 Signaling Pathway , 2021, Neurochemical Research.

[45]  Ayman E El-Sahar,et al.  Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways , 2020, The international journal of neuropsychopharmacology.

[46]  Pranav U. Damale,et al.  NF-κB signaling in astrocytes modulates brain inflammation and neuronal injury following sequential exposure to manganese and MPTP during development and aging. , 2020, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  T. Behl,et al.  Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease. , 2020, IUBMB life.

[48]  Di Wang,et al.  Forsythoside B attenuates memory impairment and neuroinflammation via inhibition on NF-κB signaling in Alzheimer’s disease , 2020, Journal of Neuroinflammation.

[49]  T. G. Singh,et al.  Role of Nuclear Factor Kappa B (NF-KB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach , 2020, Current neuropharmacology.

[50]  Arun H. Patil,et al.  Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications. , 2019, Omics : a journal of integrative biology.

[51]  Jin-jian Lu,et al.  The effects of bioactive components from the rhizome of Salvia miltiorrhiza (Danshen) on the characteristics of Alzheimer’s disease , 2019, Chinese Medicine.

[52]  K. Akashi,et al.  PUFA-Plasmalogens Attenuate the LPS-Induced Nitric Oxide Production by Inhibiting the NF-kB, p38 MAPK and JNK Pathways in Microglial Cells , 2019, Neuroscience.

[53]  Mark P. Mattson,et al.  Notch signaling and neuronal death in stroke , 2018, Progress in Neurobiology.

[54]  Izumi V. Hinkson,et al.  Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity , 2017, The Journal of experimental medicine.

[55]  V. Demarin,et al.  Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial , 2017, Neuropsychiatric disease and treatment.

[56]  B. Albensi,et al.  Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease , 2016, Front. Mol. Neurosci..

[57]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[58]  James B. Brewer,et al.  A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease , 2015, Neurology.

[59]  J. Alam Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats , 2015, Journal of Alzheimer's disease : JAD.

[60]  V. Perry,et al.  Etanercept in Alzheimer disease , 2015, Neurology.

[61]  Y. Shi,et al.  Minocycline reduces neuroinflammation but does not ameliorate neuron loss in a mouse model of neurodegeneration , 2015, Scientific Reports.

[62]  K. Abe,et al.  Long-term Effect of Telmisartan on Alzheimer’s Amyloid Genesis in SHR-SR After tMCAO , 2015, Translational Stroke Research.

[63]  M. Srinivasan,et al.  Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis , 2015, Expert opinion on therapeutic targets.

[64]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[65]  J. Yun,et al.  Mitochondrial ROS govern the LPS-induced pro-inflammatory response in microglia cells by regulating MAPK and NF-κB pathways , 2015, Neuroscience Letters.

[66]  W. Lukiw,et al.  Regulation of Neurotropic Signaling by the Inducible, NF-kB-Sensitive miRNA-125b in Alzheimer's Disease (AD) and in Primary Human Neuronal-Glial (HNG) Cells , 2014, Molecular Neurobiology.

[67]  H. Joshi,et al.  Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer’s disease , 2014, Human & experimental toxicology.

[68]  Ayae Kinoshita,et al.  Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. , 2013, The Journal of clinical investigation.

[69]  K. Sunagawa,et al.  Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. , 2012, Journal of cardiology.

[70]  J. Saavedra,et al.  Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways , 2012, Journal of Neuroinflammation.

[71]  M. Ferretti,et al.  Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology , 2012, Journal of Neuroinflammation.

[72]  N. Lajis,et al.  Cardamonin from Alpinia rafflesiana inhibits inflammatory responses in IFN-γ/LPS-stimulated BV2 microglia via NF-κB signalling pathway. , 2012, International immunopharmacology.

[73]  Navdeep S. Chandel,et al.  NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration , 2011, Nature Cell Biology.

[74]  T. Suuronen,et al.  Terpenoids: natural inhibitors of NF-κB signaling with anti-inflammatory and anticancer potential , 2008, Cellular and Molecular Life Sciences.

[75]  L. Battistin,et al.  Targeting IKK2 by pharmacological inhibitor AS602868 prevents excitotoxic injury to neurons and oligodendrocytes , 2008, Journal of Neural Transmission.

[76]  S. Ghosh,et al.  NF-κB and the immune response , 2006, Oncogene.

[77]  M. Ko,et al.  Nuclear Factor-κB Activated by Capacitative Ca2+ Entry Enhances Muscarinic Receptor-mediated Soluble Amyloid Precursor Protein (sAPPα) Release in SH-SY5Y Cells* , 2006, Journal of Biological Chemistry.

[78]  S. Akira,et al.  Essential function for the kinase TAK1 in innate and adaptive immune responses , 2005, Nature Immunology.

[79]  F. Squadrito,et al.  Glutamate promotes NF-κB pathway in primary astrocytes: protective effects of IRFI 016, a synthetic vitamin E analogue , 2005, Experimental Neurology.

[80]  A. Ciechanover,et al.  Inhibition of NF‐κB cellular function via specific targeting of the IκB‐ubiquitin ligase , 1997 .

[81]  T. Torgerson,et al.  Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.

[82]  Sukru Oter,et al.  Melatonin: An Established Antioxidant Worthy of Use in Clinical Trials , 2009, Molecular medicine.